<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
<% signal.analyst %>
Last Updated: Mar 16, 2026 04:25:18 PM (GMT)
JNJ: Current market price is 241.81, showing a decline of -0.34% from the previous price.
Support and Resistance Levels Current support levels are 241.76333, 240.01667, and 238.35333, while resistance levels are 245.17333, 246.83667, and 248.58333. The pivot point is at 243.42667.
Indicators RSI is at 74.59, indicating that it is currently overbought. ATR stands at 0.51204, indicating lower volatility. ADX is at 41.01, suggesting a strong trend. The 50-day SMA is 241.7264, while the 200-day EMA is 241.9896. The Parabolic SAR has flipped and is currently at 240.38.
Market Sentiment The market price is below the pivot point (243.42667) and indicators suggest a bearish scenario due to overbought RSI and declining trend signals.
JNJ Signals & Technical Analysis
Market Sentiment
Trend Indicators
Oscillators
Moving Averages
Pivot
About (jnj) Johnson & Johnson
Company Background
Johnson & Johnson, identified by the stock symbol JNJ and traded on the New York Stock Exchange (NYSE), is a leading multinational corporation founded in 1886. Headquartered in New Brunswick, New Jersey, the company has established itself as a pioneer in the healthcare sector, focusing on the development, manufacturing, and marketing of consumer health products, pharmaceuticals, and medical devices. With a commitment to innovation and quality, Johnson & Johnson has made significant advancements in various healthcare fields, including surgical care, immunology, infectious diseases, and orthopedics.
Market Position
As one of the most reputable brands in the global healthcare landscape, Johnson & Johnson holds a strong market position with a diverse portfolio that includes iconic consumer brands like Band-Aid, Tylenol, and Neutrogena. The company's expansive reach across over 60 countries allows it to tap into various healthcare markets, making it a formidable player in both consumer health and pharmaceutical sectors. Johnson & Johnson consistently ranks among the top pharmaceutical companies in the world, bolstered by a robust research and development (R&D) pipeline that focuses on addressing unmet medical needs.
Key Financial Highlights
Johnson & Johnson has showcased impressive financial performance, reporting annual revenues exceeding $93 billion in recent years. The company’s consistent growth trajectory is supported by strategic acquisitions and partnerships that enhance its product offerings and expand its market presence. With a strong balance sheet, JNJ maintains a solid dividend growth record, appealing to income-focused investors. The company's commitment to shareholder value is evident through its long-standing practice of dividend payments, making it a member of the Dividend Aristocrats.
In recent industry highlights, Johnson & Johnson has made headlines for its response to the COVID-19 pandemic through the development of its single-dose vaccine, demonstrating agility and innovation. The company continues to invest heavily in R&D, focusing on cutting-edge therapies and technologies that promise to reshape the future of healthcare. As a trusted name in the industry, Johnson & Johnson remains committed to improving global health outcomes while achieving sustainable growth and profitability.
Related Stocks
Sidebar rates
- <% signal.pair %>
<% signals.active.Current.rate.substr(0,7) %>
